Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Objective :To compare the analgesic effect of intrathecal midazolam and ketamine as an additive to bupivacaine in patients undergoing cesarean section .
Methods:Following Ethics Committee approval and informed patients consent, Ninety patients 18-45 yr old ASA physical status I or II, scheduled for cesarean section under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free ,the midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam and the placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally . Time to first requirement of analgesic supplement, Sensory block onset time, maximum sensory level , onset of motor block, duration of blockade, hemodynamics variables, the incidence of hypotension, ephedrine requirements, bradycardia ,hypoxemia [Saturation of peripheral oxygen (SpO2)<90], postoperative analgesic requirements and Adverse events, such as sedation, dizziness , Pruritus and postoperative nausea and vomiting were recorded. Patients were instructed preoperatively in the use of the verbal rating scale (VRS) from 0 to 10 (0no pain, 10maximum imaginable pain) for pain assessment. If the VRS exceeded four and the patient requested a supplement analgesic, diclofenac Na supp 100 mg was to be given for post-operative pain relief as needed . For breakthrough pain(VRS >4) if time of administration of diclofenac Na less than 8h,Pethidine 25 mg IV was given.
The patients were randomly allocated to one of three groups of 30 each. The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free ,the midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam and the placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ketamine | Active Comparator | The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally . |
|
| midazolam | Active Comparator | The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally |
|
| placebo | Placebo Comparator | The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally . |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| placebo(distilled water | Drug | The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally . |
|
| Measure | Description | Time Frame |
|---|---|---|
| Time to first requirement of analgesic supplement | analgesic administration was initiated by patient request(verbal rating scale[ VRS]>4) | participants will be followed for the duration of 24 hours after intratechal injection (Time from the injection of intrathecal anesthetic solution to first requirement of analgesic supplement will be recorded.) |
| Postoperative analgesic requirements | postoperative analgesic requirements will be assessed by verbal rating scale (VRS) from 0 to 10 (0no pain, 10maximum imaginable pain).Each administration was initiated by patient request( VRS>4) | 24 hours postoperative(Time from the injection of intrathecal anesthetic solution to 24 hours postoperative) |
| Measure | Description | Time Frame |
|---|---|---|
| Sensory block onset time will be assessed by a pinprick test | The onset of sensory block was defined as the time between the end of injection of the intrathecal anesthetic and the absence of pain at the T10 dermatome | sensory block will be assessed by pinprick test every 10 seconds following intrathecal injection |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Marzieh Beigom Khezri | Qazvin medical science university | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Qazvin university of medical science | Qazvin | Qazvin Province | Iran |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 24529671 | Derived | Khezri MB, Ghasemi J, Mohammadi N. Evaluation of the analgesic effect of ketamine as an additive to intrathecal bupivacaine in patients undergoing cesarean section. Acta Anaesthesiol Taiwan. 2013 Dec;51(4):155-60. doi: 10.1016/j.aat.2013.12.004. Epub 2014 Jan 21. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Ketamine | Drug | The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally |
|
| Midazolam | Drug | The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally |
|
| duration of sensory block will be assessed by a pinprick test |
The duration of sensory block was defined as the time for regression from the maximum block height sensory block to T10 dermatom will be assessed by pinprick test every 5 minuts following intrathecal injection |
| sensory block will be assessed by pinprick test every 5 minuts following intrathecal injection |
| the onset of motor block will be assessed by the modified Bromage score | The onset of motor block was defined as the time between the end of injection of the intrathecal anesthetic to Bromage block 1 | every10 seconds following intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 5min before the intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 2minutes after intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 4minutes after intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 6minutes after intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 8minutes after intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 10 minutes after intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 15minutes after intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 20 minutes after intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 25 minutes after intrathecal injection |
| hemodynamic variables are assessed by noninvasive automatic blood pressure measurement and electrocardiogram monitoring | 30 minutes after intrathecal injection |
| duration of motor block will be assessed by the modified Bromage score | duration of motor block was defined the time from intrathecal injection to Bromage score0 | every 5 minutes following intrathecal injection |
| ID | Term |
|---|---|
| D010149 | Pain, Postoperative |
| D010146 | Pain |
| ID | Term |
|---|---|
| D011183 | Postoperative Complications |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D009461 | Neurologic Manifestations |
| D012816 | Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| D008874 | Midazolam |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D009930 | Organic Chemicals |
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided